Lars Lindner is a medical oncologist having received his training as medical doctor at the University of Göttingen, Germany, and the Ludwig-Maximilians-Universitaet Munich, Germany. He spent his final year of medical school at the Cornell Medical Center, the Memorial Sloan Kettering Cancer Center and the Mount Sinai Medical College, all New York City, USA, and the Stadtspital Triemli, Zurich, Switzerland. He conducted his PhD studies with Prof. Eibl at the Max Planck Institute for Biophysical Chemistry in Göttingen, Germany, focusing on novel liposomal drug delivery technologies, and spent his Postdoctoral Fellowship at Erasmus Medical Center, Rotterdam, the Netherlands, at the Laboratory of Experimental Surgical Oncology with Prof. Dr. Alexander Eggermont. Today, he is an Professor of internal medicine, hematology and oncology at the University Hospital of the Ludwig-Maximilians-Universitaet Munich, Germany. He coordinates the Sarcoma Center SarKUM, one of Germany’s largest and leading centers dedicated to the diagnosis and treatment of cancer patients with all types of sarcomas, and the hyperthermia treatment center, one of the world’s largest and most renowned centers for regional deep hyperthermia in cancer patients. In addition, he supervises a research group dedicated to basic and applied research on novel, liposomal drug delivery technologies.
He is the inventor of several patents and author/co-author of more than 50 scientific publications and various book chapters, with a strong focus on regional deep hyperthermia as a compassionate use with chemotherapeutic-based oncological treatment regimes, sarcoma as an oncological indication, as well as thermosensitive liposomal drug delivery technologies to enhance drug-based treatment regimes in various solid tumors. He is the co-inventor of parts of Thermosome’s TSL technology and conducted extensive basic research as well as in vitro and in vivo experiments with Thermosome’s TSL technology throughout his academic career.